Journal
CURRENT OPINION IN BIOTECHNOLOGY
Volume 28, Issue -, Pages 51-58Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2013.11.005
Keywords
-
Funding
- NSF [1264701, 1011509]
- Direct For Education and Human Resources
- Division Of Graduate Education [1011509] Funding Source: National Science Foundation
- Directorate For Engineering
- Div Of Chem, Bioeng, Env, & Transp Sys [1264701] Funding Source: National Science Foundation
Ask authors/readers for more resources
Vaccine adjuvants are an essential component of vaccine design, helping to generate immunity to pathogen antigens in the absence of infection. Recent advances in nanoscale engineering have created a new class of particulate bionanotechnology that uses biomimicry to better integrate adjuvant and antigen. These pathogen-like particles, or PLPs, can come from a variety of sources, ranging from fully synthetic platforms to biologically derived, self-assembling systems. By employing molecularly engineered targeting and stimulation of key immune cells, recent studies utilizing PLPs as vaccine delivery platforms have shown great promise against high-impact, unsolved vaccine targets ranging from bacterial and viral pathogens to cancer and addiction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available